Pharmacokinetics of teicoplanin in an ICU population of children and infants

Pharmaceutical Research

Volumn 21, Issue 11, 2004, Pages 2064-2071

  Lukas, John C ^a,b   Karikas, Georgios ^c   Gazouli, Maria ^d   Kalabalikis, Panagiotis ^c   Hatzis, Tasos ^c   Macheras, Panos ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Children; Infants; NONMEM; Pharmacokinetics; Simulation; Teicoplanin

Indexed keywords

TEICOPLANIN; ANTIINFECTIVE AGENT;

AGE DISTRIBUTION; ARTICLE; BACTERIAL INFECTION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ERUPTION; ERROR; FEMALE; GRAM POSITIVE BACTERIUM; HUMAN; INFANT; INTENSIVE CARE UNIT; MALE; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STANDARD; AGING; ALGORITHM; BODY WEIGHT; FLUORESCENCE POLARIZATION IMMUNOASSAY; METABOLISM; MICROBIOLOGY; MONTE CARLO METHOD; POPULATION; PRESCHOOL CHILD; STAPHYLOCOCCUS INFECTION; STATISTICAL MODEL;

AGING; ALGORITHMS; ANTI-BACTERIAL AGENTS; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INFANT; INTENSIVE CARE UNITS; MALE; MODELS, STATISTICAL; MONTE CARLO METHOD; POPULATION; STAPHYLOCOCCAL INFECTIONS; TEICOPLANIN;

EID: 21644480083     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000048198.56873.d8     Document Type: Article

References (17)

1. H. Wisplinghoff, H. Seifert, S. M. Tallent, T. Bischoff, R. P. Wenzel, and M. B. Edmond. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. Pediatr. Infect. Dis. J. 22:686-691 (2003).
2. H. M. Aucken, M. Ganner, S. Murchan, B. D. Cookson, and A. P. Johnson. A new UK strain of epidemic methicillin-resistant Staphylococcus aureus (EMRSA-17) resistant to multiple antibiotics. J. Antimic. Chemother. 50:171-175 (2002).
3. A. P. Johnson, C. Henwood, S. Mushtaq, D. James, M. Warner, and D. M. Livermore. ICU Study Group. Susceptibility of gram-positive bacteria from ICU patients in UK hospitals to antimicrobial agents. J. Hosp. Infect. 54:179-187 (2003).
4. J. Cepeda, S. Hayman, T. Whitehouse, C. C. Kibbler, D. Livermore, M. Singer, and A. P. Wilson. Teicoplanin resistance in methicillin-resistant Staphylococcus aureus in an intensive care unit. J. Antimicrob. Chemother. 52:533-534 (2003).
5. J. M. Hamilton-Miller. Vancomycin-resistant Staphylococcus aureus: a real and present danger? Infecion 30:118-124 (2002).
6. G. L. Drusano. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin. Infect. Dis. 15((Suppl 1)):42-50 (2003).
7. G. L. Traina and M. Bonati. Pharmacokinetics of teicoplanin in man after intravenous administration. J. Pharmacokinet. Biopharm. 12:119-128 (1984).
8. J. D. Knudsen, K. Fuursted, S. Raber, F. Espersen, and N. Frimodt-Moller. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection. Antimicrob. Agents Chemother. 44:1247-1254 (2000).
9. P. Vaudaux, P. Francois, B. Berger-Bachi, and D. P. Lew. In vivo emergence of subpopulations expressing teicoplanin or vancomycin resistance phenotypes in a glycopeptide-susceptible methicillin-resistant strain of Staphylococcus aureus. J. Antimicrob. Chemother. 47:163-170 (2001).
10. M. Rowland. Clinical pharmacokinetics of teicoplanin. Clin. Pharmacokinet. 18:184-209 (1990).
11. A. P. Wilson. Clinical pharmacokinetics of teicoplanin. Clin. Pharmacokinet. 39:167-183 (2000).
12. V. Fanos, M. Mussap, B. J. Khoory, S. Vecchini, M. Plebani, and D. Benini. Renal tolerability of teicoplanin in a case of neonatal overdose. J. Chemother. 10:381-384 (1998).
13. A. Louie, P. Kaw, W. Liu, N. Jumpe, M. H. Miller, and G. L. Drusano. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob. Agents Chemother. 45:845-851 (2001).
14. N. Jauregizar, J. A. Wald, A. Astobieta, J. M. Rodriguez Sasiain, J. C. Lucas, and R. Calvo. Population pharmacokinetics of netilmicin in short term prophylactic treatment. Br. J. Clin. Pharmacol. 55:552-559 (2003).
15. A. Sanchez, J. Lopez-Herce, E. Cueto, A. Camllo, and R. Moral. Teicoplanin pharmacokinetics in critically ill paediatric patients. J. Antimicrob. Chemother. 44:407-409 (1999).
16. D. R. Butler, R. J. Kuhn, and M. H. Chandler. Pharmacokinetics of anti-infective agents in paediatric patients. Clin. Pharmacokinet. 26:374-395 (1994).
17. R. F. Reinoso, B. A. Telfer, B. S. Brennan, and M. Rowland. Uptake of teicoplanin by isolated rat hepatocytes: comparison with in vivo hepatic distribution. Drug Metab. Dispos. 29:453-459 (2001).